DSM Biologics has signed a contract with NKT Therapeutics, Inc. for the process development and cGMP manufacture of NKT’s lead product iNKT mAb. NKT, based in Waltham, MA, is a biotechnology company that focuses on developing therapeutics based on immune cells called natural killer T (NKT) cells. Financial terms of the contract were not disclosed. NKT cells are a central part of the immune system. When exposed to microbial and viral pathogens, NKT cells secrete high levels of specific cytokin...